In order not to compromise the availability of the veterinary medicinal products concerned, it is necessary to provide for transitional measures to allow marketing authorisation holders, the competent authorities or, where the veterinary medicinal product is authorised under the centralised marketing authorisation procedure, the Commission, sufficient time to amend existing marketing authorisations with a view to ensuring consistency with the provisions of this Regulation.
Recital 21, Regulation (EU) 2024/1159
In forcesince 7 Feb 2024